These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30825248)

  • 1. Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as non-nucleoside hepatitis B virus inhibitors by exploring the solvent-exposed region.
    Yu J; Jia H; Guo X; Desta S; Zhang S; Zhang J; Ding X; Liang X; Liu X; Zhan P
    Chem Biol Drug Des; 2020 Jun; 95(6):567-583. PubMed ID: 30825248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors.
    Jia H; Yu J; Du X; Cherukupalli S; Zhan P; Liu X
    Eur J Med Chem; 2020 Sep; 202():112495. PubMed ID: 32712535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
    Ma Y; Zhao S; Ren Y; Cherukupalli S; Li Q; Woodson ME; Bradley DP; Tavis JE; Liu X; Zhan P
    Eur J Med Chem; 2021 Dec; 225():113780. PubMed ID: 34438123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
    Qiu J; Gong Q; Gao J; Chen W; Zhang Y; Gu X; Tang D
    Eur J Med Chem; 2018 Jan; 144():424-434. PubMed ID: 29288943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
    Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
    Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents.
    Gu X; Zhang Y; Zou Y; Li X; Guan M; Zhou Q; Qiu J
    Bioorg Med Chem; 2021 Jan; 29():115892. PubMed ID: 33285406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents.
    Liu Y; Peng Y; Lu J; Wang J; Ma H; Song C; Liu B; Qiao Y; Yu W; Wu J; Chang J
    Eur J Med Chem; 2018 Jan; 143():137-149. PubMed ID: 29174810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors.
    Jia H; Bai F; Liu N; Liang X; Zhan P; Ma C; Jiang X; Liu X
    Eur J Med Chem; 2016 Nov; 123():202-210. PubMed ID: 27484509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
    Liu S; Wei W; Li Y; Liu X; Cao X; Lei K; Zhou M
    Eur J Med Chem; 2015 May; 95():473-82. PubMed ID: 25847765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors.
    Jia H; Song Y; Yu J; Zhan P; Rai D; Liang X; Ma C; Liu X
    Eur J Med Chem; 2017 Aug; 136():144-153. PubMed ID: 28494252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors.
    Pan T; Ding Y; Wu L; Liang L; He X; Li Q; Bai C; Zhang H
    Eur J Med Chem; 2019 Mar; 166():480-501. PubMed ID: 30739828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    Wang J; Zhang H; Zhang Y; Jiang D; Li J; Goldmann S; Ren Q; Fei R; Wang X; Wei L
    J Med Virol; 2017 Oct; 89(10):1804-1810. PubMed ID: 28401569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new series of HAPs as anti-HBV agents targeting at capsid assembly.
    Yang XY; Xu XQ; Guan H; Wang LL; Wu Q; Zhao GM; Li S
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4247-9. PubMed ID: 25127104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.
    Boucle S; Lu X; Bassit L; Ozturk T; Russell OO; Amblard F; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2017 Feb; 27(4):904-910. PubMed ID: 28094179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, molecular docking studies and anti-HBV activity of phenylpropanoid derivatives.
    Liu S; Li Y; Wei W; Wang K; Wang L; Wang J
    Chem Biol Interact; 2016 May; 251():1-9. PubMed ID: 26980103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
    Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS
    Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction.
    Tsukamoto Y; Ikeda S; Uwai K; Taguchi R; Chayama K; Sakaguchi T; Narita R; Yao WL; Takeuchi F; Otakaki Y; Watashi K; Wakita T; Kato H; Fujita T
    PLoS One; 2018; 13(5):e0197664. PubMed ID: 29782545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors.
    Qiu J; Chen W; Zhang Y; Zhou Q; Chen J; Yang L; Gao J; Gu X; Tang D
    Eur J Med Chem; 2019 Aug; 176():41-49. PubMed ID: 31091479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
    Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
    J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.
    Zhao J; Tu J; Fan N; Chen X; Lu F; Zhang Y; Zhang L; Tian C; Zhang Z; Liu J; Wang X
    Future Med Chem; 2016 May; 8(7):751-63. PubMed ID: 27172826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.